When was Galaxy founded?

Galaxy was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Galaxy located?

Galaxy is headquartered in Seoul, South Korea.

Is Galaxy a funded company?

Galaxy is a funded company, having raised a total of $47M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2022.

When was the latest funding round of Galaxy?

Galaxy's latest funding was a $***** Series B round on Feb 09, 2026, with participation from 8 investors.

Where does Galaxy rank among its competitors?

Galaxy ranks 19th amongst 78 active competitors, of which 42 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Galaxy, which secured $29M in Feb, 2026.

Who are the top competitors of Galaxy?

Galaxy's top competitors include Nimbus Therapeutics, Generate Biomedicines and Cradle. Among them, Galaxy secured the most recent funding round in February, 2026.

Galaxy - 2026 Company Profile, Team, Funding & Competitors

Galaxy is a series B company based in Seoul (South Korea), founded in 2020. It operates as a Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various biomolecules. Galaxy has raised $47M in funding from InterVest and Daily Partners. The company has 78 active competitors, including 42 funded and 5 that have exited. Its top competitors include companies like Nimbus Therapeutics, Generate Biomedicines and Cradle.

Company Details

Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various biomolecules. The technology enables the prediction of solubility, binding affinity, and other properties of these molecules, which is crucial in the drug discovery process. The platform helps in molecular design, protien structure prediction, protien interaction and prediction for drug development.

Website: galux.co.kr
Email ID: *****@galux.co.kr

Key Metrics

Founded Year

2020

Location

Seoul, South Korea

Stage

Series B

Total Funding

$47M in 2 rounds

Latest Funding Round

Series B, Feb 09, 2026, $*****

Investors

InterVest & 8 more

Ranked

19^th among 78 active competitors

Similar Companies

Nimbus Therapeutics & 82 more

View Galaxy's full profile

Galaxy has raised a total funding of $47M over 2 rounds. Its first funding round was on 2022. Its latest funding round was a Series B round on Feb 09, 2026 for $*****. 8 investors participated in its latest round. Galaxy has 9 institutional investors.

Here is the list of recent funding rounds of Galaxy:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 09, 2026	5506103	Series B	8435150	7036059	1205134	5487086
2022	5564	Series A	2421	1896	9989	6004

Access funding benchmarks and valuations. Sign up today!

View details of Galaxy's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Galaxy include Nimbus Therapeutics, Generate Biomedicines and Cradle. Here is the list of Top 10 competitors of Galaxy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	NVentures, March Capital & 14 others	66/100
3rd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, IVP & 7 others	64/100
4th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Insight Partners, Altimeter Capital & 6 others	64/100
5th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	64/100
6th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, ADIA & 22 others	62/100
7th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Bessemer Venture Partners, Lightspeed Venture Partners ... & 12 others	61/100
8th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Versant Ventures & 21 others	61/100
9th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, University of Oxford ... & 11 others	59/100
10th	Nomic 2017, Montreal (Canada), Series B	Provider of next-generation proteomics platform for drug discovery and protein analysis	$63M	Lux Capital, Amplitude & 13 others	56/100
19th	Galaxy 2020, Seoul (South Korea), Series B	Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various biomolecules	$47M	Ncore Ventures, Korean Development Bank & 7 others	46/100